Literature DB >> 27776044

Homeobox-Only Protein Expression Is a Critical Prognostic Indicator of Pancreatic Neuroendocrine Tumor and Is Regulated by Promoter DNA Hypermethylation.

Hideki Ushiku1, Keishi Yamashita, Hiroshi Kawamata, Mina Waraya, Hiroshi Katoh, Keigo Yokoi, Toshimichi Tanaka, Satoru Ishii, Nobuyuki Nishizawa, Mariko Kikuchi, Naoko Minatani, Ken Kojo, Hiroshi Tajima, Ryo Nishiyama, Takashi Kaizu, Yusuke Kumamoto, Masahiko Watanabe.   

Abstract

OBJECTIVES: We have identified homeobox-only protein (HOPX) as a tumor suppressor gene in various human cancer, and its expression was reduced by promoter DNA hypermethylation. Homeobox-only protein is strongly expressed on pancreatic islet cells; however, clinical relevance of HOPX expression has remained elusive in pancreatic neuroendocrine tumor (pNET).
METHODS: We investigated 36 patients with pNET who undertook surgical resection between 1988 and 2012 for HOPX expression and DNA methylation to reveal its clinical significance.
RESULTS: (1) Homeobox-only protein is strongly expressed on pancreatic islet cells by immunohistochemistry (IHC). Homeobox-only protein expression was recognized on pNET tumor cells for 1+ in 15, for 2+ in 16, and for 3+ in 5. (2) Homeobox-only protein IHC expression was significantly associated with prognosis (P = 0.03), and survival rate was 37.5%, 70.3%, and 100% in HOPX 1+, 2+, and 3+, respectively. (3) Promoter DNA methylation was quantitatively assessed, and HOPX hypermethylation is found in 6.3%, 11.8%, and 66.7% of G1/G2/G3 pNET, respectively (P = 0.02). (4) Multivariate Cox proportional hazards model identified HOPX IHC expression and HOPX promoter DNA hypermethylation as independent prognostic factors in pNET.
CONCLUSIONS: Homeobox-only protein expression is a critical prognostic indicator of pNET, and its regulation may be made through promoter DNA methylation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27776044     DOI: 10.1097/MPA.0000000000000646

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  7 in total

Review 1.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

2.  Linkage mapping combined with association analysis reveals QTL and candidate genes for three husk traits in maize.

Authors:  Zhenhai Cui; Aiai Xia; Ao Zhang; Jinhong Luo; Xiaohong Yang; Lijun Zhang; Yanye Ruan; Yan He
Journal:  Theor Appl Genet       Date:  2018-07-24       Impact factor: 5.699

Review 3.  Analysis of DNA Methylation Status in Bodily Fluids for Early Detection of Cancer.

Authors:  Keigo Yokoi; Keishi Yamashita; Masahiko Watanabe
Journal:  Int J Mol Sci       Date:  2017-03-30       Impact factor: 5.923

4.  HOPX homeobox methylation in differentiated thyroid cancer and its clinical relevance.

Authors:  Erika Urbano Lima; Ileana G S Rubio; Joaquim Custodio Da Silva; Ana Luiza Galrão; Danielle Pêssoa; Taise Cerqueira Oliveira; Fabiane Carrijo; Igor Silva Campos; Luciano Fonseca Espinheira; Luiz Jose Sampaio; Claudio Rogerio Lima; Janete Maria Cerutti; Helton Estrela Ramos
Journal:  Endocr Connect       Date:  2018-12       Impact factor: 3.335

Review 5.  Role of DNA Methylation in the Resistance to Therapy in Solid Tumors.

Authors:  Susana Romero-Garcia; Heriberto Prado-Garcia; Angeles Carlos-Reyes
Journal:  Front Oncol       Date:  2020-08-07       Impact factor: 5.738

Review 6.  Epigenetics of gastroenteropancreatic neuroendocrine tumors: A clinicopathologic perspective.

Authors:  Brendan M Finnerty; Katherine D Gray; Maureen D Moore; Rasa Zarnegar; Thomas J Fahey Iii
Journal:  World J Gastrointest Oncol       Date:  2017-09-15

7.  Epigenetic silencing of HOPX is critically involved in aggressive phenotypes and patient prognosis in papillary thyroid cancer.

Authors:  Yosuke Ooizumi; Hiroshi Katoh; Mitsuo Yokota; Masahiko Watanabe; Keishi Yamashita
Journal:  Oncotarget       Date:  2019-10-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.